CRISPR Therapeutics AG (CRSP) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CRSP SEC filings page.
CRISPR Therapeutics AG (CRSP) reported $13.4M in revenue over the twelve months to Jun 30, 2026, down 64.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
CRISPR Therapeutics operates as a research platform, with substantial development spending, recurring cash outflows, and little current revenue.
From FY2023 to FY2025, reported revenue fell from$371M to$3.5M while R&D remained$285M , showing that spending is driven by development activity rather than near-term sales volume. That combination makes reported revenue a poor gauge of the company's operating scale today.
In FY2025, the net loss was
The balance sheet is lightly debt-funded: no long-term debt was reported, while liabilities were
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of CRISPR Therapeutics AG's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
CRISPR Therapeutics AG held $2.0B in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $345.0M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and CRISPR Therapeutics AG scores 71/100 among other emerging companies.
CRISPR Therapeutics AG had 96M shares outstanding at the end of fiscal year 2025, against 86M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and CRISPR Therapeutics AG scores 49/100 among other emerging companies.
CRISPR Therapeutics AG spent $284.8M on research and development in fiscal year 2025, which was 42.6% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and CRISPR Therapeutics AG scores 73/100 among other emerging companies.
CRISPR Therapeutics AG reported revenue of $3.5M in fiscal year 2025, against $37.3M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and CRISPR Therapeutics AG scores 1/100 among other emerging companies.
CRISPR Therapeutics AG's operations used $345.0M of cash in fiscal year 2025, against $142.8M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and CRISPR Therapeutics AG scores 33/100 among other emerging companies.
CRISPR Therapeutics AG's cash, cash equivalents and investments came to $2.0B at the end of fiscal year 2025, against $343.4M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and CRISPR Therapeutics AG scores 90/100 among other emerging companies.
CRISPR Therapeutics AG scores 7.12, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($4.8B) relative to total liabilities ($343.4M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
CRISPR Therapeutics AG passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
CRISPR Therapeutics AG reported a net loss of $581.6M while operations used $345.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
CRISPR Therapeutics AG generated $10.2M in revenue in Q2 2026. This represents an increase of 1041.4% from the same quarter a year earlier. Against the prior quarter it is up 598.3%.
CRISPR Therapeutics AG's EBITDA was -$113.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 49.7% from the same quarter a year earlier. Against the prior quarter it is up 10.3%.
CRISPR Therapeutics AG reported -$91.2M in net income in Q2 2026. This represents an increase of 56.3% from the same quarter a year earlier. Against the prior quarter it is up 25.8%.
CRISPR Therapeutics AG earned -$0.94 per diluted share (EPS) in Q2 2026. This represents an increase of 60.8% from the same quarter a year earlier. Against the prior quarter it is up 26.6%.
Cash & Balance Sheet
CRISPR Therapeutics AG recorded an outflow of $84.1M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 26.2% from the same quarter a year earlier. Against the prior quarter it is up 23.1%.
CRISPR Therapeutics AG held $291.3M in cash against $586.2M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
CRISPR Therapeutics AG's ROE was -5.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 7.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.5 percentage points.
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
CRISPR Therapeutics AG invested $67.2M in research and development in Q2 2026. This represents a decrease of 3.9% from the same quarter a year earlier. Against the prior quarter it is down 2.1%.
CRISPR Therapeutics AG invested $648K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 453.8% from the same quarter a year earlier. Against the prior quarter it is up 28.6%.
Not reported for Q2 2026.
CRSP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.2M+1041.4% | $1.5M+68.6% | $864K-97.6% | $889K+47.7% | $892K+72.5% | $865K+71.6% | $35.7M | $602K |
| R&D Expenses | $67.2M-3.9% | $68.6M-5.4% | $83.5M+16.4% | $58.9M-28.3% | $69.9M-12.8% | $72.5M-4.8% | $71.7M | $82.2M-9.4% |
| SG&A Expenses | $17.6M-7.2% | $17.2M-11.0% | $18.4M+1.5% | $16.9M-2.8% | $18.9M-2.9% | $19.3M+7.5% | $18.1M | $17.4M-4.8% |
| Operating Income | -$117.3M+48.9% | -$130.2M+12.2% | -$154.8M-139.6% | -$132.1M-19.9% | -$229.3M-51.6% | -$148.4M-5.6% | -$64.6M | -$110.1M+16.8% |
| EBITDA | -$113.0M+49.7% | -$125.9M+12.4% | -$149.0M-149.4% | -$127.7M-21.2% | -$224.7M-53.4% | -$143.7M-5.8% | -$59.8M | -$105.3M+17.4% |
| Interest Expense | $3.3M | $553K | N/A | N/A | $0 | $0 | N/A | N/A |
| Income Tax | $960K-25.7% | $839K-24.3% | $614K-12.3% | $619K-29.3% | $1.3M+0.4% | $1.1M+53.2% | $700K | $876K+112.6% |
| Net Income | -$91.2M+56.3% | -$122.9M+9.6% | -$130.6M-250.1% | -$106.4M-23.9% | -$208.5M-65.0% | -$136.0M-16.6% | -$37.3M | -$85.9M+23.4% |
| EPS (Basic) | -$0.94+60.8% | -$1.28+19.0% | -$1.35-221.4% | -$1.17-15.8% | -$2.40-61.1% | -$1.58-10.5% | -$0.42-137.2% | -$1.01+28.4% |
| EPS (Diluted) | -$0.94+60.8% | -$1.28+19.0% | -$1.35-221.4% | -$1.17-15.8% | -$2.40-61.1% | -$1.58-10.5% | -$0.42-137.2% | -$1.01+28.4% |
| Diluted Shares (Avg) | 97M+10.8% | 96M+11.8% | N/A | 91M+7.1% | 87M+2.5% | 86M+5.1% | N/A | 85M+7.3% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
CRSP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.7B+30.6% | $2.7B+25.8% | $2.3B+1.0% | $2.2B-0.5% | $2.0B-13.3% | $2.2B-11.2% | $2.2B+0.6% | $2.3B+8.1% |
| Current Assets | $2.4B+36.8% | $2.4B+31.1% | $2.0B+2.5% | $1.9B-0.8% | $1.7B-13.8% | $1.9B-11.9% | $1.9B+1.5% | $1.9B+10.4% |
| Cash & Equivalents | $291.3M+50.5% | $423.3M+80.0% | $347.6M+16.5% | $286.5M+27.0% | $193.6M-60.0% | $235.2M-66.8% | $298.3M-23.4% | $225.7M-57.2% |
| Short-Term Investments | $2.1B+35.7% | $2.0B+24.6% | $1.6B+1.4% | $1.6B-4.7% | $1.5B+0.7% | $1.6B+15.7% | $1.6B+23.1% | $1.7B+41.1% |
| Accounts Receivable | N/A | N/A | $0-100.0% | $0 | $0 | $0 | $25.0M-87.5% | $0 |
| Long-Term Investments | $0 | $0 | $0 | $28.4M | $0-100.0% | $0 | $0-100.0% | $0 |
| Total Liabilities | $904.2M+183.8% | $911.3M+170.5% | $343.4M+10.8% | $329.3M+4.1% | $318.6M-11.2% | $336.9M-5.1% | $310.0M-10.6% | $316.5M-11.9% |
| Current Liabilities | $132.9M+27.3% | $136.3M+14.1% | $149.1M+69.9% | $119.0M+32.5% | $104.4M-18.4% | $119.4M+0.4% | $87.8M-19.3% | $89.8M-19.3% |
| Non-Current Liabilities | $771.3M+260.1% | $775.0M+256.3% | $194.3M-12.5% | $210.4M-7.2% | $214.2M-7.3% | $217.5M-7.9% | $222.2M-6.6% | $226.7M-8.5% |
| Long-Term Debt | $586.2M | $585.5M | $0 | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.7B+2.1% | $1.8B-0.8% | $1.9B-0.5% | $1.9B-1.2% | $1.7B-13.6% | $1.8B-12.2% | $1.9B+2.6% | $1.9B+12.3% |
| Retained Earnings | -$2.2B-26.4% | -$2.1B-37.9% | -$1.9B-42.6% | -$1.8B-36.8% | -$1.7B-37.6% | -$1.5B-34.5% | -$1.4B-36.6% | -$1.3B-22.0% |
Not reported in any period shown, so not listed: Inventory, Goodwill.
CRSP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$83.5M+26.7% | -$108.9M-101.9% | -$92.6M-85.0% | -$84.6M+20.8% | -$113.9M-19.1% | -$53.9M-149.2% | -$50.0M+47.9% | -$106.9M-168.2% |
| Depreciation & Amortization | $4.3M-6.5% | $4.3M-8.8% | $5.7M+16.9% | $4.4M-8.3% | $4.6M-4.2% | $4.7M-2.0% | $4.8M-1.2% | $4.8M-2.0% |
| Stock-Based Compensation | $17.3M-1.7% | $16.3M-19.2% | N/A | $16.6M-22.9% | $17.6M-25.6% | $20.2M+4.2% | N/A | $21.5M+7.9% |
| Capital Expenditures | $648K+453.8% | $504K+144.7% | $517K+103.5% | $74K-66.2% | $117K-83.5% | $206K-71.4% | $254K-65.6% | $219K-89.7% |
| Free Cash Flow | -$84.1M+26.2% | -$109.4M-102.0% | -$93.1M-85.1% | -$84.7M+20.9% | -$114.0M-18.4% | -$54.2M-149.7% | -$50.3M+48.1% | -$107.1M-155.2% |
| Investing Cash Flow | -$55.7M-179.5% | -$410.7M-1979.2% | $37.2M-64.8% | -$119.2M+26.2% | $70.0M+155.1% | -$19.8M+79.8% | $105.8M+229.9% | -$161.6M-233.2% |
| Financing Cash Flow | $7.2M+218.0% | $591.9M+5490.4% | $116.4M+589.8% | $296.8M+2978.5% | $2.3M+584.5% | $10.6M-96.5% | $16.9M-56.7% | $9.6M+519.5% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
CRSP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1151.8% | -8933.3% | -17912.5% | -14854.8% | -25709.0% | -17158.8% | -181.0% | -18294.0% |
| Net Margin | -895.3% | -8431.5% | -15117.3% | -11973.1% | -23379.9% | -15722.1% | -104.5% | -14276.1% |
| Return on Equity | -5.2%+7.0pp | -6.8%+0.7pp | -6.8%-4.9pp | -5.6%-1.1pp | -12.2%-5.8pp | -7.4%-1.8pp | -1.9% | -4.4%+2.1pp |
| Return on Assets | -3.4%+6.8pp | -4.5%+1.8pp | -5.8%-4.1pp | -4.7%-0.9pp | -10.3%-4.9pp | -6.3%-1.5pp | -1.7% | -3.8%+1.6pp |
| Current Ratio | 17.85+1.2x | 17.96+2.3x | 13.32-8.8x | 16.22-5.4x | 16.61+0.9x | 15.64-2.2x | 22.07+4.5x | 21.64+5.8x |
| Debt-to-Equity | 0.34+0.1x | 0.32+0.1x | 0.00-0.2x | 0.170.0x | 0.190.0x | 0.180.0x | 0.160.0x | 0.160.0x |
| Asset Turnover | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.02 | 0.000.0x |
| FCF Margin | -826.5% | -7503.5% | -10772.0% | -9528.5% | -12779.9% | -6260.5% | -140.9% | -17796.0% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| CRISPR Therapeutics AG CRSP | FY2025 | $3.5M | -$581.6M | N/A | $4.8B | 53/100 |
| Merus N.V. MRUS | FY2024 | $36.1M | -$215.3M | N/A | $6.8B | 59/100 |
| TG Therapeutics, Inc. TGTX | FY2025 | $616.3M | $447.2M | 72.6% | $8.3B | 60/100 |
| PTC Therapeutics, Inc. PTCT | FY2025 | $1.7B | $683.0M | 39.5% | $4.9B | 53/100 |
| Legend Biotech Corporation LEGN | FY2025 | $1.0B | -$296.8M | -28.8% | $3.6B | 41/100 |
Where CRISPR Therapeutics AG Ranks
Frequently Asked Questions
What is CRISPR Therapeutics AG's annual revenue?
CRISPR Therapeutics AG (CRSP) reported $3.5M in total revenue for fiscal year 2025. This represents a -90.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is CRISPR Therapeutics AG's revenue growing?
CRISPR Therapeutics AG (CRSP) revenue declined by 90.6% year-over-year, from $37.3M to $3.5M in fiscal year 2025.
Is CRISPR Therapeutics AG profitable?
No, CRISPR Therapeutics AG (CRSP) reported a net income of -$581.6M in fiscal year 2025.
What is CRISPR Therapeutics AG's EBITDA?
CRISPR Therapeutics AG (CRSP) had EBITDA of -$645.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does CRISPR Therapeutics AG have?
As of fiscal year 2025, CRISPR Therapeutics AG (CRSP) had $347.6M in cash and equivalents against $0 in long-term debt.
What is CRISPR Therapeutics AG's return on equity (ROE)?
CRISPR Therapeutics AG (CRSP) has a return on equity of -30.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is CRISPR Therapeutics AG's free cash flow?
CRISPR Therapeutics AG (CRSP) recorded an outflow of $345.9M in free cash flow during fiscal year 2025. This represents a -139.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is CRISPR Therapeutics AG's operating cash flow?
CRISPR Therapeutics AG (CRSP) recorded an outflow of $345.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are CRISPR Therapeutics AG's total assets?
CRISPR Therapeutics AG (CRSP) had $2.3B in total assets as of fiscal year 2025, including both current and long-term assets.
What are CRISPR Therapeutics AG's capital expenditures?
CRISPR Therapeutics AG (CRSP) invested $914K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does CRISPR Therapeutics AG spend on research and development?
CRISPR Therapeutics AG (CRSP) invested $284.8M in research and development during fiscal year 2025.
What is CRISPR Therapeutics AG's current ratio?
CRISPR Therapeutics AG (CRSP) had a current ratio of 13.32 as of fiscal year 2025, which is generally considered healthy.
What is CRISPR Therapeutics AG's debt-to-equity ratio?
CRISPR Therapeutics AG (CRSP) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is CRISPR Therapeutics AG's return on assets (ROA)?
CRISPR Therapeutics AG (CRSP) had a return on assets of -25.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is CRISPR Therapeutics AG's P/E ratio?
CRISPR Therapeutics AG (CRSP) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $4.8B as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is CRISPR Therapeutics AG's price-to-sales ratio?
CRISPR Therapeutics AG (CRSP) trades at 356x sales, its market capitalization divided by revenue of $13.4M revenue, trailing 12 months to June 30, 2026. The market capitalization is $4.8B as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does CRISPR Therapeutics AG's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, CRISPR Therapeutics AG (CRSP) held $2.0B in cash, cash equivalents and investments, and reported an operating cash outflow of $345.0M over that year. Dividing the one by the other, the reported balance equals about 69 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is CRISPR Therapeutics AG's Altman Z-Score?
CRISPR Therapeutics AG (CRSP) has an Altman Z-Score of 7.12, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is CRISPR Therapeutics AG's Piotroski F-Score?
CRISPR Therapeutics AG (CRSP) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are CRISPR Therapeutics AG's earnings high quality?
CRISPR Therapeutics AG (CRSP) reported a net loss of $581.6M while operations used $345.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is CRISPR Therapeutics AG?
CRISPR Therapeutics AG (CRSP) scores 53 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.